Introduction: The role of prophylactic cranial irradiation (PCI) is controversial in patients with extensive stage small cell lung cancer. The aim of this study was to determine the impact of PCI in these patients.
Introduction
Small cell lung cancer (SCLC) is fatal neuroendocrine tumor accounting for approximately 15% of all lung cancers. 1 It is characterized by rapid growth and early dissemination, and brain metastasis is a common problem in patients with SCLC. [1] [2] [3] Considering that the blood-brain barrier prevents most cytotoxic agents from penetrating into the brain and that SCLC is radiosensitive, a number of trials have investigated the role of prophylactic cranial irradiation (PCI) in SCLC patients who showed complete response after initial therapy.
The effectiveness of PCI has been well established in patients with limited-stage (LS) SCLC after response to first-line therapy. [5] [6] [7] [8] [9] Meanwhile, there is controversy over the appropriateness of PCI for patients with extensive-stage (ES) SCLC. 10 The first study focusing on the impact of PCI in patients with ES-SCLC who responded to initial chemotherapy was published by the European Organization for Research and Treatment of Cancer (EORTC) in 2007. 11 This study revealed that PCI reduced the incidence of symptomatic brain metastasis and increased overall survival (OS) compared with observation. 11 Subsequent studies also provided supporting data that PCI was associated with better survival in patients with ES-SCLC. [12] [13] [14] [15] According to a recent survey analysis, 98% of U.S. radiation oncologists recommended PCI for ES-SCLC when there is no evidence of brain metastases on brain magnetic resonance imaging (MRI) after initial chemotherapy. 10 However, there has been continuous debate about the performance of PCI in patients with ES-SCLC based on the EORTC study because of reasons including (1) uncertainty of brain metastasis at baseline, (2) uncertainty of cisplatin-containing regimens at baseline, (3) variations in the total irradiation dose and the number of fractions, and (4) a study on the incidence of symptomatic brain metastasis instead of OS. 16 Recently, a prospective randomized controlled trial (RCT) conducted in the Japan Clinical Oncology Group (JCOG) did not show a survival benefit with PCI in patients with ES-SCLC. 16 The appearance of this conflicting trial caused controversy regarding the appropriateness of PCI for patients with ES-SCLC.
Therefore, the role of PCI has remained unclarified in patients with ES-SCLC. Systematic reviews and metaanalyses on the application of PCI for SCLC after response to first-line therapy have been previously published. 4, 17, 18 However, there is no meta-analysis focusing on the role of PCI in patients with ES-SCLC. The aim of this study was to perform a systematic review and meta-analysis to determine the role of PCI in patients with ES-SCLC who received PCI.
Materials and Methods

Data Sources and Search Strategy
We searched three electronic databases (MEDLINE, EMBASE, and the Cochrane Central Register) in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 19 We used the following terms: "small cell lung cancer" or "small cell lung carcinoma" or "SCLC"; "prophylactic" or "preventive"; and "intracranial" or "brain" and "irradiation" or "radiation therapy" or "radiation treatment." The search encompassed studies published up to December 15, 2017. Reference lists of every article were retrieved, and relevant reviews were examined manually to further identify potentially relevant studies. The detailed study protocol and search strategies are provided in the supplementary data. As this study was a systematic review of published articles, neither informed consent nor ethics approval was required.
Inclusion and Exclusion Criteria
All the studies were included in this meta-analysis if they met the following inclusion criteria: (1) a phase II or III RCT that directly compared PCI and no PCI; (2) patients with a diagnosis of ES-SCLC; (3) the outcome of interest was OS; and (4) risk estimates and 95% confidence intervals (CIs) were reported (or the information to calculate them was available). Studies targeting patients with non-SCLC and LS-SCLC were excluded. Studies published as full-length articles in peer-reviewed English language journals were eligible for inclusion. Review articles, abstracts, case reports, commentaries, and studies reporting outcomes but without raw data were excluded.
Data Extraction and Quality Assessment
Two authors independently retrieved potentially relevant studies, reviewed each study according to the predefined criteria for eligibility, and finally extracted data. Any disagreements that arose during the process of study selection or data extraction were resolved by discussion. A predefined form was used to extract data from each study. The primary endpoint was OS, which was defined as the interval from the date of randomization until the date of death from any cause. Secondary endpoints were 1-year survival rate, progression-free survival (PFS) and the risk of brain metastasis. PFS was defined as the interval from the date of randomization until the date of documented progression or death from any cause. The risk of brain metastasis was defined as the occurrence from the date of randomization until the date of diagnosis of brain metastasis on the basis of brain MRI or computed tomography performed by either protocol-based check-up or the presence of symptoms suggestive of brain metastasis.
Methodological quality and risk of bias were evaluated for each trial using the Cochrane collaboration for RCTs. 20 Discrepancies were resolved by consensus between the two authors.
Data Synthesis and Statistical Analysis
We extracted the hazard ratios (HRs) and associated 95% CIs for OS, PFS, and risk of brain metastasis to assess treatment efficacy within the PCI group. Unless published HRs were available, we derived estimates from other survival data using the methods of Parmar, 21 and we calculated the pooled relative risk using the Mante-Haenszel method for 1-year survival rate and adverse events (AEs). Between-study statistical heterogeneity was assessed using I 2 and the Cochrane Q test. 22 Heterogeneity was assessed using I 2 statistics on a scale of 0% to 100%. A fixed-effects model was used unless I 2 was >50%, indicating a substantial level of betweenstudy heterogeneity, in which case a random-effects model was used. 22 In cases of substantial heterogeneity, analysis via meta-regression was performed to identify potential sources of bias. 23 We performed the subgroup analysis according to median age (65 years versus <65 years), screening for baseline brain metastases (confirmed versus not confirmed), and duration of follow-up (36 months versus <36 months). We also conducted sensitivity analyses to evaluate the influence of individual studies in analyses with substantial heterogeneity of the overall effect estimate. The influence of each study was estimated by removing each in turn from the analysis and identifying whether the effect size and significance of the treatment effect were changed or not. The publication bias for OS analysis was assessed using the Begg Figure 1 presents the literature search process. A total of 1,081 published articles were initially identified (399 articles from MEDLINE, 573 articles from EMBASE, and 109 articles from the Cochrane library). After removing duplicate articles, we screened 843 potentially eligible articles. After reviewing the title and abstracts, 818 search records were removed, and the remaining 25 articles were further evaluated by reading the full text. Nineteen articles were excluded for the reasons shown in Figure 1 . Finally, five studies were included in our final analysis. [11] [12] [13] 16, 26 
Results
Study Search and Characteristics and Quality of Included Studies
Primary Endpoint
Pooled estimates of the treatment efficacy for OS of the PCI group were weighted and combined using the generic inverse-variance and random effect model. In pooled estimates, there was no significant difference in OS between PCI and no-PCI patients (HR ¼ 0.82; 95% CI: 0.60-1.11; I 2 ¼ 77%; p ¼ 0.19) (Fig. 2) . When the analysis was restricted to primary analysis with regard to study design, there was also no statistically significant difference in OS between both groups (HR ¼ 0.93; 95% CI: 0.50-1.71;
To investigate the effect of each individual study on the overall metaanalysis estimate, we performed sensitivity analysis by calculating the pooled HRs with successive exclusion of one study. In particular, one study had a significantly different OS estimate than the other studies. 15 After excluding that study, 16 patients who received PCI had better survival than patients who did not receive PCI, and heterogeneity decreased (HR ¼ 0.72; 95% CI: 0.57-0.92; I 2 ¼ 39%; p ¼ 0.009). We also performed subgroup analysis for OS according to median age, screening for baseline brain metastases, and the duration of follow-up. When the analysis was restricted to patients with median age < 65 years and unidentified brain metastases at baseline, OS was significantly higher in the PCI group (HR ¼ 0. Fig. 3 ). Because a substantial degree of heterogeneity existed among the trials, the meta-regression technique was used to explore heterogeneity. Specifically, we investigated study design, age, and screening for baseline brain metastases as probable sources of heterogeneity, and there were no significant factors identified (Table 2) .
Secondary Endpoints
In pooled estimates, the 1-year survival rate was 37.1% (95% CI: 32.7-41.6) and 27.1% (95% CI: 23.5-31.0) in the PCI group and the no-PCI group, respectively. The pooled estimates using a fixed-effect model with the Mante-Haenszel method showed a significant survival advantage in the PCI group (risk ratio ¼ 0.87; 95% CI: 0.80-0.95; I 2 ¼ 47%; p ¼ 0.002) (Fig. 3A) . Three trials with a total of 595 patients compared PFS between the PCI and no-PCI groups in patients with ES-SCLC. 11, 16, 26 Progression was less likely in the PCI group than in the no-PCI group (HR ¼ 0.83; 95% CI: 0.70-0.98; I 2 ¼ 22%; p ¼ 0.03) (Fig. 3B) . The risk of brain metastasis was reported in two trials with a total of 714 patients. 11, 16 The pooled estimates indicated that the risk of brain metastasis was significantly lower in the PCI group than in the no-PCI group (HR ¼ 0.34; 95% CI: 0.23-0.50; I 2 ¼ 0%; p < 0.001) (Fig. 3C) .
Discussion
In the present study, we investigated the impact of PCI in patients with ES-SCLC who responded to initial therapy using a systemic review and meta-analysis approach. In the pooled estimates, there was no significant OS advantage in the group assigned to PCI compared with the no-PCI group. However, substantial heterogeneity was identified in the pooled estimates in both groups. Although we investigated potential sources of heterogeneity, they were not identified in metaregression analysis. In the sensitivity and subgroup analysis, specific patients in the PCI group had significantly higher OS, and 1-year OS was significantly improved and PFS was significantly greater in the PCI group. Furthermore, PCI reduced the risk of brain metastasis in patients with ES-SCLC.
On the basis of the results from the EORCT study, 11 the 2013 American College of Chest Physicians guideline on the treatment of SCLC stated that PCI was recommended in ES-as well as LS-SCLC patients who achieved a complete or partial response to initial therapy. 7 However, based on the preliminary data of the JCOG trial, 16 the American Society of Clinical Oncology guideline in 2015 suggested that the recommendation for PCI in ES-SCLC patients might be subject to revision. 7 In addition, the current guideline of the National Comprehensive Cancer Network also suggested that PCI should be considered in patients with ES-SCLC, not recommended. 9 After the official publication of the JCOG trial, 16 the controversy over administration of PCI in patients with ES-SCLC was increased. [27] [28] [29] In the present study, a sensitivity analysis excluding a JCOG study showed that patients who were treated with PCI showed an OS advantage compared to those treated without PCI. Our interpretation of the results of sensitivity analysis is as follows. First, there is screening for baseline brain metastases. Unless brain imaging was a standard component of initial staging with the incorporation of brain MRI, a substantial number of patients might already have brain metastases at randomization. 27 Therefore, improved OS in some patients may be affected by the efficacy of whole-brain irradiation for known brain metastasis. 27 In line with this hypothesis, our pooled estimates for trials that did not confirm the absence of brain metastases at baseline revealed improvement in OS. A JCOG study rigorously enrolled patients who had been confirmed not to have brain metastases by MRI before randomization. 16 Second, the JCOG trial performed active brain MRI surveillance after PCI. 16 In that trial, 47.8% (54 of 113 patients) of patients in the PCI group developed brain metastases, and 46.3% (25 of 54 patients) of these patients underwent repeat cranial irraidation. 16 On the other hand, the EORTC study reported that symptomatic brain metastases were observed in 16.8% (24 of 143 patients) of patients in the PCI group, and repeat cranial irradiation was administered in only 8.4% (2 of 124 patients) of these patients. 11 A large, multicenter RCT revealed that higher PCI of 36G was associated with lower 2-year OS rate in patients with LS-SCLC compared to standard PCI of 25G (37% versus 42%; p ¼ 0.05). 30 Although most patients who underwent repeat cranial irraidation in the JCOG trial received stereotactic radiotherapy instead of whole-brain irradiation, 31 repeat cranial irradiation might have a negative effect on OS. Also, frequent performance of brain MRI could have a negative impact on quality of life in patients with ES-SCLC. 29 Third, this may be because the JCOG trial included relatively elderly patients. 16 Because OS was defined as any cause of death, the etiology of death in elderly patients might not be cancer-related. We conducted subgroup analysis to address these considerations and showed that patients with median age less than 65 years in the PCI group were associated with improved OS. Similarly, follow-up duration differed among included studies. The median followup interval varied from 9 to 100 months. Given a longer follow-up time, the probability of cancer-related mortality as a proportion of total mortality would likely decline. Although our study did not show that duration of followup greater than or equal to 36 months was associated with decreased OS in the PCI group, the small sample size did not allow us to draw a robust conclusion. Therefore, further analyses evaluating the efficacy of PCI on OS according to follow-up duration are necessary. Finally, differences of salvage chemotherapy among trials could have an effect on the OS of PCI. 27 Although we could not investigate the efficacy of salvage chemotherapy due to the limited data, the impact of these differences on the treatment of brain metastases from SCLC remains unclear. 32 Considering these findings, sequential new trials are needed. In the modern MRI era, the administration of routine brain MRI at baseline for ES-SCLC has been well established. 9 However, because it is difficult to standardize active brain MRI surveillance until the detection of brain metastases in many countries, additional studies comparing the clinical outcomes between PCI and active brain MRI surveillance are warranted. Also, further large-scale RCTs are necessary to determine the role of PCI in OS in patients with ES-SCLC according to group differences such as age, duration of follow-up time, and systemic salvage therapy.
We additionally found nonrandomized trials for the role of PCI in patients with ES-SCLC. 14, 15, 33 These recent trials reported a significant improvement in median OS in patients with ES-SCLC who received PCI compared to those who did not receive the therapy. 14, 15, 33 But, because nonrandomized design can cause bias as arms are generally not well balanced, we did not include these studies in the present analysis.
The main difference between the EORTC study and other studies in our meta-analysis was the primary endpoint. In the EORTC study, the primary endpoint was development of brain metastases, 11 and it could still be regarded as an important outcome when evaluating the efficacy of PCI in ES-SCLC. A systematic review revealed that whole-brain irradiation on brain metastases had a substantial impact on the quality of life and increased cost burden in patients with non-SCLC. 34 Our pooled estimates showed that PCI significantly reduced the Figure 3 . Paired forest plots of (A) relative-risk for death in 1 year, and hazard ratios for (B) progression-free survival, and (C) the risk of brain metastasis in patients with extensive stage small cell lung cancer who received PCI versus no PCI. SE, standard error; CI, confidence interval; IV, inverse variance; df, degrees of freedom; and PCI, prophylactic cranial irradiation; and M-H, Mante-Haenszel method. development of brain metastases in patients with ES-SCLC. With respect to the quality of life and health care cost, PCI on ES-SCLC would be valuable in practice.
Although we tried to investigate the AEs including grade 3 or higher overall toxicity and neurotoxicity after PCI, the pooled analysis could be not conducted due to the limited data. In the EORTC study, PCI had AEs but did not have clinically significant effects on global health status, role function, cognitive functioning, or emotional functioning between the two groups. 11 A JCOG study also reported that the grade 3 or higher overall toxicity did not differ significantly between the groups. 16 According to previous trials, the clinical significance of AEs after PCI remains unclear. 3, [35] [36] [37] Especially, long-term neurotoxicity after PCI is a crucial problem. A pooled secondary analysis of the Radiation Therapy Oncology Group trials revealed that PCI was associated with a decline in selfreported cognitive functioning in patients with lung cancer. 36 The persistence of these AEs might decrease OS as well as quality of life in the PCI group. 16 This would elicit concerns about the applications of PCI in ES-SCLC.
To our knowledge, this is the first meta-analysis to investigate the role of PCI in patients with ES-SCLC. However, the potential limitations of our study should be considered when interpreting the results. First, the sample size in the present study was small, and did not have enough statistical power to explore the real associations. Second, there was statistically significant heterogeneity in the selected studies. Although we explored the heterogeneity using meta-regression, we failed to find the source. Third, although publication bias was determined to be low by statistical analysis, the possibility of publication bias cannot be fully excluded.
In conclusion, PCI has not been shown to improve OS in ES-SCLC patients. Instead, because the subgroup and sensitivity analysis showed some OS benefit, this therapy would be helpful in selected patients. In addition, PCI had benefit for 1-year survival, PFS, and risk of the brain metastasis. Further trials are needed to establish the performance of PCI in specific ES-SCLC patients according to unresolved factors such as active brain MRI surveillance, age, duration of follow-up time, and systemic salvage therapy.
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